Prostate cancer highlights from ASCO 2025 include data on niraparib and acetate plus prednisone, terbium-161 for targeting micrometastases, and predictors of response in the ENZA-p trial.

In an interview with Pharmaceutical Executive, Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discussed the company’s expanding efforts in solid tumors, a space where it is still ...

Dr. Joshua K. Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Annual Meeting, highlighting what patients should ...

Stay up-to-date with the latest advancements in oncology by watching an insightful video interview with experts from The Leukemia & Lymphoma Society about blood cancers and future trends in cancer ...

With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past weekend, Johnson & Johnson and its latest lung cancer campaign towered ...

Lymphoma highlights from ASCO 2025 include data on CAR-T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R Hodgkin lymphoma.

Inside ASCO 2025: Big data drops and a towering campaign By Ayla Ellison, Angus Liu, Gabrielle Masson, Zoey Becker Jun 6, 2025 10:39am The Top Line ASCO 2025 Enhertu Johnson & Johnson ...

Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago. At-home intervention has potential to enhance cancer care delivery, outcomes. Source: Nipp RD, et al. Abstract 11003.

Latest Advances in AML Treatment from ASCO 2025: Exploring Oral Regimens and Comparative Effectiveness : Episode 1. Opinion. Video. June 30, 2025. Unmet Needs and Emerging Trends in AML: ASCO 2025 ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival ...

Optimizing Outcomes After Transoral Robotic Surgery for Oropharyngeal Carcinoma: Reflections on the ASCO Guideline. The following represents disclosure information provided by authors of this ...

ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...